Evidence map›Paper›PMID 40273067›Full record

ArticlePloS one2025

COVID-19 pandemic and risk factor measurement in individuals with cardio-renal-metabolic diseases: A retrospective study in the United Kingdom.

Sharmin Shabnam, Francesco Zaccardi, Tom Yates, Nazrul Islam, Cameron Razieh, Yogini V Chudasama, Amitava Banerjee, Samuel Seidu, Kamlesh Khunti, Clare L Gillies

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sharmin ShabnamLeicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, United Kingdom.ORCID 0000-0002-2519-1240
Francesco ZaccardiLeicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, United Kingdom.
Tom YatesNational Institute for Health Research (NIHR) Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester General Hospital, Leicester, United Kingdom.
Nazrul IslamPrimary Care Research Centre, University of Southampton, Southampton, United Kingdom.
Cameron RaziehLeicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, United Kingdom.
Yogini V ChudasamaLeicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, United Kingdom.
Amitava BanerjeeInstitute of Health Informatics, University College London, London, United Kingdom.ORCID 0000-0001-8741-3411
Samuel SeiduLeicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, United Kingdom.
Kamlesh KhuntiLeicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, United Kingdom.
Clare L GilliesLeicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundComprehensive research about changes in risk factor (RF) management of people with chronic conditions during the COVID-19 pandemic is sparse. We aimed to study the impact of the pandemic on RF assessment in people with type 2 diabetes (T2DM), cardiovascular disease (CVD), and chronic kidney disease (CKD).

methodUsing UK Clinical Practice Research Datalink GOLD, we identified adults with T2DM, CVD and CKD who were alive and registered two years before (March 2018 - February 2019; March 2019 - February 2020) and one year during (March 2020 - February 2021) the pandemic. We estimated the proportion of people whose RFs (systolic (SBP) and diastolic (DBP) blood pressure, total cholesterol (TC), body mass index, smoking, and HbA1c) were assessed, mean values, and the proportion of controlled at each period for each cohort, overall and by age, sex, ethnicity, and deprivation. Multivariable logistic regression was used to estimate the association of patient characteristics (age, sex, ethnicity, deprivation, and comorbidity) with the outcome of having all RFs assessed during a given period.

resultsWithin the T2DM cohort, 66.4% and 65.2% had assessments of HbA1c in 2018 and 2019, which reduced to 43.4% in 2020. In CVD cohort, 76.9% and 72.6% had their BP measurements (54.5% and 51.3% for TC) in 2018 and 2019 respectively, which declined to 40.6% (30.7% for TC) in 2020. In CKD cohort, BP assessments declined from 77.9% and 72.3% in 2018 and 2019 respectively to 45.0% in 2020. These findings were consistent across patient demographics. In those with T2DM, SBP and DBP increased (+1.65 mmHg and +1.02 mmHg) in 2020. Elderly people were less likely to have all their RFs assessed in 2020 in all three cohorts compared to previous years.

conclusionsAmong people with major cardiometabolic conditions, there have been substantial reductions in the assessment and control of several key RFs during the pandemic. These patients will need regular monitoring in future for the prevention of complications. Our findings also highlight the need for resilient healthcare systems to ensure continuity of care and mitigate disparities in high-risk populations.

Indexed as

Cardiovascular DiseasesCOVID-19Diabetes Mellitus, Type 2Renal Insufficiency, ChronicAdultAgedBlood PressureComorbidityFemaleGlycated HemoglobinHumansMaleMiddle AgedPandemicsRetrospective StudiesRisk FactorsGlycated Hemoglobin

Identifiers

PMID40273067
PMCPMC12021215

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.